$1.70
15.68% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US59564R2031
Symbol
BDRX
Sector
Industry

Midatech Pharma Plc Sponsored ADR Stock price

$1.47
-1.48 50.17% 1M
-4.54 75.53% 6M
-2.58 63.70% YTD
-26.03 94.65% 1Y
-38,398.53 100.00% 3Y
-50,798.53 100.00% 5Y
-14,699,998.53 100.00% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.07 4.55%
ISIN
US59564R2031
Symbol
BDRX
Sector
Industry

Key metrics

Market capitalization $850.00k
Enterprise Value $-5.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.52
EV/Sales (TTM) EV/Sales -50.60
P/S ratio (TTM) P/S ratio 8.50
P/B ratio (TTM) P/B ratio 0.12
Revenue growth (TTM) Revenue growth -83.72%
Revenue (TTM) Revenue $100.00k
EBIT (operating result TTM) EBIT $-10.08m
Free Cash Flow (TTM) Free Cash Flow $-9.70m
EPS (TTM) EPS $-49.74
P/E forward negative
Short interest 9.29%
Show more

Is Midatech Pharma Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Midatech Pharma Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Midatech Pharma Plc Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Midatech Pharma Plc Sponsored ADR:

Buy
100%

Financial data from Midatech Pharma Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
0.10 0.10
84% 84%
100%
- Direct Costs 0.35 0.35
-
350%
-0.24 -0.24
-
-240%
- Selling and Administrative Expenses 4.45 4.45
11% 11%
4,450%
- Research and Development Expense 5.04 5.04
15% 15%
5,040%
-9.74 -9.74
9% 9%
-9,740%
- Depreciation and Amortization 0.35 0.35
5% 5%
350%
EBIT (Operating Income) EBIT -10 -10
9% 9%
-10,083%
Net Profit -8.58 -8.58
12% 12%
-8,580%

In millions USD.

Don't miss a Thing! We will send you all news about Midatech Pharma Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Midatech Pharma Plc Sponsored ADR Stock News

Neutral
Accesswire
16 days ago
CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treat...
Neutral
GlobeNewsWire
25 days ago
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical c...
Neutral
GlobeNewsWire
29 days ago
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical comp...

Company Profile

Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The company engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. Its pipeline includes MTD119, MTX102, MTD201 and MTX110. Midatech Pharma was founded on September 12, 2014 and is headquartered in Cardiff, the United Kingdom.

Head office United Kingdom
CEO Stephen Stamp
Founded 2000
Website www.biodexapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today